Zepbound (Tirzepatide) for Weight Loss

What Is Zepbound?

Zepbound is the brand name for tirzepatide when prescribed for chronic weight management. It is manufactured by Eli Lilly and Company and was FDA-approved on November 8, 2023, for use in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol — alongside a reduced-calorie diet and increased physical activity 1Ref 1Abbasi J (2023).FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management.FDA approval date (November 8, 2023), approved indication, BMI thresholds, drug class description.

The same molecule, tirzepatide, is also sold as Mounjaro, a formulation approved for type 2 diabetes. Zepbound and Mounjaro are pharmacologically identical but carry different FDA approvals and labeling. This mirrors the semaglutide situation: Ozempic (diabetes) and Wegovy (weight loss) contain the same active ingredient at different approved doses and indications.

How Zepbound Works: A Dual Mechanism

Zepbound is the first approved weight-loss drug to activate two gut-hormone receptors simultaneously 1Ref 1Abbasi J (2023).FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management.FDA approval date (November 8, 2023), approved indication, BMI thresholds, drug class description:

• GLP-1 (glucagon-like peptide-1) receptor: Signals the brain to reduce appetite, stimulates the pancreas to release insulin in proportion to blood sugar, and slows gastric emptying so food stays in the stomach longer.
• GIP (glucose-dependent insulinotropic polypeptide) receptor: A second gut hormone that appears to amplify GLP-1's appetite-suppressing effects and may improve the body's sensitivity to insulin.

This dual-agonist action is why tirzepatide produces greater average weight loss than semaglutide, which activates only the GLP-1 receptor. The combined signaling reduces caloric intake — not by willpower, but by altering the hormonal environment that governs hunger and satiety 2Ref 2Jastreboff AM, Aronne LJ, Ahmad NN, et al., for the SURMOUNT-1 Investigators (2022).Tirzepatide Once Weekly for the Treatment of Obesity.SURMOUNT-1 primary results: 16.0–22.5% weight loss at 72 weeks by dose; proportion achieving ≥5% and ≥20% thresholds; dual GLP-1/GIP mechanism.

Clinical Trial Results

SURMOUNT-1 (72-week phase 3 trial): In a double-blind, randomized, placebo-controlled trial of 2,539 adults with obesity or overweight without diabetes, tirzepatide produced dose-dependent weight loss at 72 weeks 2Ref 2Jastreboff AM, Aronne LJ, Ahmad NN, et al., for the SURMOUNT-1 Investigators (2022).Tirzepatide Once Weekly for the Treatment of Obesity.SURMOUNT-1 primary results: 16.0–22.5% weight loss at 72 weeks by dose; proportion achieving ≥5% and ≥20% thresholds; dual GLP-1/GIP mechanism:

• 5 mg/week: mean 16.0% body weight reduction
• 10 mg/week: mean 21.4% body weight reduction
• 15 mg/week: mean 22.5% body weight reduction
• Placebo: mean 2.4% body weight reduction

Approximately 91% of participants on the 15 mg dose lost at least 5% of body weight; 57% lost at least 20% 2Ref 2Jastreboff AM, Aronne LJ, Ahmad NN, et al., for the SURMOUNT-1 Investigators (2022).Tirzepatide Once Weekly for the Treatment of Obesity.SURMOUNT-1 primary results: 16.0–22.5% weight loss at 72 weeks by dose; proportion achieving ≥5% and ≥20% thresholds; dual GLP-1/GIP mechanism.

SURMOUNT-5 (head-to-head vs. semaglutide): A phase 3b, randomized trial published in the NEJM in 2025 compared tirzepatide directly against weekly semaglutide (Wegovy) in 751 adults with obesity without diabetes over 72 weeks. Participants on tirzepatide lost an average of 20.2% of body weight versus 13.7% on semaglutide — a difference of approximately 6.5 percentage points 3Ref 3Jastreboff AM, le Roux CW, Stefanski A, et al. (SURMOUNT-5 Investigators) (2025).Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.SURMOUNT-5 head-to-head trial: tirzepatide 20.2% vs. semaglutide 13.7% weight loss at 72 weeks; cardiometabolic outcomes. Tirzepatide also produced greater reductions in waist circumference and cardiometabolic risk markers including blood pressure, HbA1c, fasting insulin, and triglycerides.

SUMMIT (heart failure trial): A separate phase 3 trial examined tirzepatide in 731 patients with heart failure with preserved ejection fraction (HFpEF) and obesity. In secondary analyses, tirzepatide produced an 11.6% body weight reduction and significantly reduced systolic blood pressure, circulating blood volume, C-reactive protein, and cardiac troponin T — suggesting cardiometabolic benefits beyond weight loss alone 4Ref 4Borlaug BA, Zile MR, Kramer CM, et al. (2024).Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.SUMMIT trial secondary analysis: 11.6% weight reduction, blood pressure reduction, CRP reduction, improved 6-minute walk distance, reduced troponin T in HFpEF patients.

Side Effects and Safety

Most common adverse reactions in clinical trials were gastrointestinal and tended to emerge during dose escalation 1Ref 1Abbasi J (2023).FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management.FDA approval date (November 8, 2023), approved indication, BMI thresholds, drug class description:

• Nausea (most frequent, especially in the first weeks)
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain

In the SURMOUNT-1 meta-analysis, 4.7–7.3% of tirzepatide-treated participants discontinued due to gastrointestinal effects, compared with 2.7–3.2% on placebo 5Ref 5Qin W, Yang J, Ni Y, et al. (2024).Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.Pooled discontinuation rates due to GI adverse events (4.7–7.3% tirzepatide vs. 2.7–3.2% placebo); GI safety profile described as generally mild to moderate and transient. These reactions are generally described as mild to moderate and often improve as the body adjusts to each dose level.

Serious but rare risks include:

• Pancreatitis
• Gallbladder disease and gallstones
• Acute kidney injury (typically from dehydration during severe GI illness)
• Hypersensitivity reactions including anaphylaxis and angioedema
• Heart rate increases of 5–10 beats per minute on average

FDA Boxed Warning — Thyroid C-cell tumors: In animal studies, tirzepatide caused dose-dependent thyroid C-cell tumors. Whether this risk applies to humans is unknown. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1Ref 1Abbasi J (2023).FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management.FDA approval date (November 8, 2023), approved indication, BMI thresholds, drug class description.

Zepbound is not recommended during pregnancy.

Dosing and How It Is Administered

Zepbound is injected subcutaneously (under the skin of the abdomen, thigh, or upper arm) once per week, on the same day each week 1Ref 1Abbasi J (2023).FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management.FDA approval date (November 8, 2023), approved indication, BMI thresholds, drug class description. The escalation schedule is designed to minimize GI side effects:

• Weeks 1–4: 2.5 mg once weekly (starting dose)
• Weeks 5–8: 5 mg once weekly
• If higher doses are needed: Increase by 2.5 mg increments every 4 weeks to 7.5 mg, 10 mg, 12.5 mg, or the maximum dose of 15 mg

The medication is available in prefilled autoinjector pens and, more recently, single-dose vials. The dose is escalated gradually — not rushed — because the slow titration is what makes the drug tolerable for most people.

Who Qualifies and Who Should Not Use Zepbound

FDA-approved criteria for use [1]:

• Adults with a BMI of 30 or higher (obesity), OR
• Adults with a BMI of 27 or higher (overweight) with at least one weight-related condition: high blood pressure, type 2 diabetes, dyslipidemia, or obstructive sleep apnea

Zepbound is used alongside a reduced-calorie diet and increased physical activity — not as a standalone substitute for lifestyle change.

Contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Serious hypersensitivity reaction to tirzepatide or any ingredient in Zepbound
• Pregnancy (stop at least 2 months before a planned pregnancy)

Weight regain after stopping is typical. Research on semaglutide (a related GLP-1 drug) showed participants regained roughly two-thirds of lost weight within a year of discontinuation. Similar patterns are expected with tirzepatide, which is why prescribers generally treat obesity as a chronic condition requiring long-term management.

Cost and Insurance Coverage

The list price of Zepbound is approximately $1,086 per month regardless of dose. Several ways to reduce this cost exist:

• Eli Lilly savings card (commercial insurance): Reduces out-of-pocket cost for eligible patients with private insurance.
• Single-dose vials via LillyDirect: Eli Lilly launched self-pay single-dose vials priced starting at $299/month for the 2.5 mg dose, rising with dose level — a significant reduction for self-pay patients.
• Eli Lilly patient assistance program: Available for patients below certain income thresholds.

Insurance coverage for weight management drugs remains inconsistent. Many employer-sponsored plans have excluded GLP-1 drugs for obesity from their formularies. Some plans that cover Mounjaro for type 2 diabetes do not cover Zepbound for weight loss, even though both contain tirzepatide.

Medicare Part D coverage for Zepbound in non-diabetic patients with obesity-only indications remains limited. Patients with established cardiovascular disease may have broader access under some plans.

Prior authorization is common when coverage is available — typically requiring documented BMI threshold and a weight-related comorbidity.